Podcasts Health & Fitness Medicine The Peter Attia Drive #148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program

#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program

Published: Feb. 8, 2021, 10:30 a.m.

b'

Richard Miller is a professor of pathology and the Director of the Center for Aging Research at the University of Michigan. He is one of the architects of the NIA-funded Interventions Testing Programs (ITPs) animal study test protocol. In this episode, Rich goes through the results of the long list of molecules tested by the ITP\\u2014including rapamycin, metformin, nicotinamide riboside, an SGLT-2 inhibitor called canagliflozin, and more. Many of the discussed outcomes have had surprising outcomes\\u2014both positive and negative findings.

We discuss:

  • Rich\\u2019s interest in aging, and how Hayflick\\u2019s hypothesis skewed aging research (3:45);
  • Dispelling the myth that aging can\\u2019t be slowed (15:00);
  • The Interventions Testing Program\\u2014A scientific framework for testing whether drugs extend lifespan in mice (29:00);
  • Testing aspirin in the first ITP cohort (38:45);
  • Rapamycin:\\xa0results from ITP studies, dosing considerations, and what it tells us about early- vs. late-life interventions (44:45);
  • Acarbose as a potential longevity agent by virtue of its ability to block peak glucose levels (1:07:15);
  • Resveratrol: why it received so much attention as a longevity agent, and the takeaways from the negative results of the ITP study (1:15:45);
  • The value in negative findings: ITP studies of green tea extract, methylene blue, curcumin, and more (1:24:15);
  • 17\\u03b1-Estradiol:\\xa0lifespan effects in male mice, and\\xa0sex-specific effects of different interventions (1:27:00);
  • Testing ursolic acid and hydrogen sulfide: rationale\\xa0and preliminary results (1:33:15);
  • Canagliflozin (an SGLT2 inhibitor): exploring the impressive lifespan results in male mice\\xa0(1:35:45);
  • The failure of metformin: reconciling\\xa0negative results of the ITP\\xa0with\\xa0data in human studies (1:42:30);
  • Nicotinamide riboside:\\xa0insights from the negative results of the ITP study (1:48:45);
  • The three most important takeaways from the ITP studies (1:55:30);
  • Philosophies on studying the aging process: best model organisms, when to start interventions, which questions to ask, and more (1:59:30);
  • Seven reasons why pigs can\'t fly (2:08:00); and
  • More.
Learn more:\\xa0https://peterattiamd.com/
\\xa0
Show notes page for this episode: https://peterattiamd.com/RichardMiller\\xa0
\\xa0
Subscribe to receive exclusive subscriber-only content:\\xa0https://peterattiamd.com/subscribe/
\\xa0
Sign up to receive Peter\'s email newsletter:\\xa0https://peterattiamd.com/newsletter/
\\xa0
Connect with Peter on Facebook | Twitter | Instagram.
'